

TOP 10 NET AMOUNT PAID (Chart 2)

Therapeutic Category	PRODUCT_NAME	GENERIC NAME	LABELER_NAME	Brand or Generic (B/G)	LIST ID (1=1yr 5=5yr)	Rank by Net Amount Paid of Drugs that Met Threshold 1= Highest Net Spend	PERCENT_INCREASE (Over One Year or Five Years)	GROSS AMOUNT PAID in CY2018	Specialty (Yes/No)	Appeared on previous list (Year)	Appeared on this year's GROSS (WAC) COST LIST
Immune Modulator	STELARA	ustekinumab	JANSSEN BIOTECH, INC	B	5	6	52%	\$ 2,127,932.77	Y	N	N
					1	2	21%				
ADHD	METHYLPHENIDATE HYDROCHLO	methylphenidate	WATSON PHARMA, INC.	G	1	1	17%	\$ 1,461,928.15	N	N	N
COPD	COMBIVENT RESPIMAT		BOEHRINGER INGELHEIM PHARMACEUTICALS	B	1	6	50%	\$ 589,079.93	N	N	N
Gastrointestinal	NEXIUM	esomeprazole	ASTRAZENECA PHARMACEUTICALS LP	B	5	1	440%	\$ 498,765.15	N	N	N
					1	3	201%				
Antidepressant	PRISTIQ	desvenlafaxine	WYETH LABORATORIES	B	5	2	730%	\$ 421,231.63	N	Y	N
					1	4	67%				
HIV	GENVOYA		GILEAD SCIENCES, INC.	B	1	5	44%	\$ 390,000.94	N	N	N
Antipsychotic	INVEGA		JANSSEN PHARMACEUTICALS, INC	B	5	5	131%	\$ 316,988.97	N	N	N
					1	9	27%				
Diabetes	CONTOUR NEXT BLOOD GLUCOSE TEST STRIPS	BG Test Strips	Bayer Diabetes Care	B	5	3	65%	\$ 250,205.15	N	N	N
					1	7	24%				
Pain (Neuropathic)	LIDODERM	lidocaine	ENDO PHARMACEUTICALS, INC.	B	5	4	213%	\$ 195,698.61	N	Y	N
					1	8	20%				
antiarrhythmic	TIKOSYN	dofetilide	PFIZER LABORATORIES DIV PFIZER INC	B	5	9	422%	\$ 125,610.99	N	N	N
					1	10	45%				